Achema middle east

News

Treating brain disorders with new nanoparticle drug delivery system

A new nanoparticle drug-delivery system could help scientists overcome the long-standing problem of delivering therapeutics across the blood-brain barrier and into the brain. Progress has been...

Forge Biologics receives US FDA approval to initiate phase 1/2 trial of AAV gene therapy, FBX-101 to treat Krabbe disease

Forge Biologics Inc., a gene therapy manufacturing and development company, announced that the company has received FDA clearance of the Investigational New Drug (IND) to...

Pfizer, OPKO One Step Closer to Approval of Pediatric Growth Hormone Deficiency Drug

Pfizer and OPKO Health are one step closer to receiving approval for their jointly developed pediatric growth hormone deficiency (GHD) drug, somatrogon, after the U.S....

Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that Israel’s Ministry of Health (MOH) has given authorization to import the...

RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that preliminary top-line data from its U.S. Phase 2 study with orally-administered opaganib (Yeliva®, ABC294640)1 in patients...

CEPI Partners with Biological E. Limited to advance Development and Manufacture of COVID-19 Vaccine candidate

CEPI, the Coalition for Epidemic Preparedness Innovationsand Biological E Limited, India (Bio E), a Hyderabad-based vaccines and pharmaceutical company, today announced a collaboration to advance...

COVAXINTM – India’s First indigenous COVID-19 Vaccine

COVAXINTM, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »